0

0

0

0

0

0

0

0

0

This article is more than 5 month old.

Zydus Cadila’s ZyCoV-D, first COVID-19 vaccine in India for children gets nod from regulator; all details here

Mini

Zydus Cadila's vaccine will be administered in three doses – first on day zero, second on day 28, and third on day 56.

Zydus Cadila’s ZyCoV-D, first COVID-19 vaccine in India for children gets nod from regulator; all details here
The Drugs Controller General of India on August 20 gave approval for emergency use to ZyCoV- D vaccine, the world’s first plasmid DNA jab developed by Zydus Cadila for COVID-19.
The three-dose jab, which can also be administered to adolescents aged 12 and above, is the second indigenous vaccine to receive the nod, after Bharat Biotech’s Covaxin.
Here’s is everything you need to know about Zydus Cadila’s ZyCoV-D
Plasmid DNA technology
ZyCoV-D will inject genetically engineered plasmids that carry the code for the SARS-CoV-2 virus. This will trigger the production of the spike protein of COVID-19 and stimulate immuno-response. Though similar to the messenger RNA technology, DNA vaccines can be redesigned to various mutations.
At present, all vaccines that have been approved or are under clinical trials use technologies such as the viral vector (J&J, Sputnik V and AstraZeneca), messenger RNA (Pfizer and Moderna), whole virus (Bharat Biotech, Sinopharm, Sinovac) and protein subunit (Novavax). These vaccines give instructions to the body to produce a fragment of the spike protein that creates antibodies.
Advantages of DNA vaccine
  • DNA vaccines are said to be cheap, safe and stable.
  • Since ZycoV-D uses a plasmid DNA platform, it does not have any problems associated with vector-based immunity
  • ZyCoV-D can be stored at 2-8 degree C for at least three months. The vaccine has shown promising stability at 25 degree C as well. Such thermostability makes the vaccine easy to transport and store.
  • As it does not use the live virus, it has a biosafety level of 1 as against Covaxin, which is at level 3, meaning production of the vaccine can easily be scaled up
  • Efficacy
    Zydus Cadila has said that ZycoV-D (2 mg per dose) was tested on 28,000 volunteers,including 1,000 volunteers in the age of 12-18 years, across more than 50 centres. The vaccine has shown robust immunogenicity and tolerance, especially among adolescents. It showed a 66.6 percent efficacy in symptomatic COVID-19 positive cases and 100 percent efficacy in moderate cases.
    As trials were held during the peak of the second COVID-19 wave, the vaccine shows efficacy against new mutant strains such as the Delta variant. The pharma firm now plans to seek approval for its two-dose regimen (3 mg per dose).
    Doses and inoculation
    Apart from being the first DNA-based vaccine, ZyCoV- D is also the first needle-free vaccine. It will be administered in three doses – first on day zero, second on day 28, and third on day 56. A special applicator called the PharmaJet will be used to administer the intradermal vaccine painlessly.
    Pricing
    Amid speculation that the three-dose vaccine may have a higher price, Cadila has said it is in talks with regulatory authorities on pricing and will provide more clarity over the next one to two weeks.
    Crucial to India’s vaccination plans
    Zydus Cadila’s vaccine is set to give India’s inoculation drive a shot in the arm as the parma firm is preparing to manufacture 10-12 crore doses annually. The company hopes to roll out the vaccine by the end of September and scale up manufacturing to one crore doses by October. It expects a larger pick from the age group of 12 to 18 years.
    next story